Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 48Neoplasms 13Sarcoma 10Neoplasm Metastasis 9Triple Negative Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 5Sarcoma, Ewing 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Colorectal Neoplasms 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Metastatic HER2-positive Breast Cancer 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma 1Lung Neoplasms 1Inoperable Locally Advanced HER2-Negative Breast Cancer 1HR+HER2- Breast Cancer 1HER2-low Breast Cancer 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

pembrolizumab 51Nivolumab 27Gemcitabine 23atezolizumab 19Cisplatin 18Carboplatin 18enfortumab vedotin 15avelumab 15Mitomycin 14Docetaxel 8Ipilimumab 7Paclitaxel 6Injections 5Cyclophosphamide 5vinflunine 4toripalimab 4tislelizumab 4lenvatinib 4fludarabine 4epacadostat 4Pemetrexed 4130-nm albumin-bound paclitaxel 4sacituzumab govitecan 3disitamab vedotin 3Rogaratinib 3Interleukin-2 3ALT-803 3vofatamab 2valrubicin 2rucaparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Transitional Cell × eribulin × Clear all
NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡